Collaboration with Eli Lilly

Physiomics PLC
17 September 2007


Collaboration with Eli Lilly

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is
pleased to announce that it has signed an agreement  with Eli Lilly and Company
('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silico
simulations of cancer cellular processes in support of Lilly's cancer drug
discovery research.

Physiomics will deploy its modelling expertise in biological systems, in close
collaboration with Lilly's global PK/PD/TS (pharmacokinetics, pharmacodynamics
and trial simulation) department and oncology discovery group. The research
programme will initially be focused on drugs targeting the cell cycle (the
natural process of controlling cell proliferation) - a process that is
frequently disrupted in cancers.

Dr Christophe Chassagnole, COO of Physiomics, said:

'We are delighted that Lilly has chosen Physiomics as a partner in the systems
biology field applied to our special focus area of oncology. This is a very
positive step forward for Physiomics as a further major pharma company joins our
growing list of partners at a time when interest in application of systems
biology to pharma R&D is increasing very rapidly.'

Contact Details:

Physiomics plc: Dr Christophe Chassagnole, phone [phone]
E-mail: [e-mail]

Grant Thornton Corporate Finance: Philip Secrett and Colin Aaronson, phone 
[phone]

Information on Physiomics plc
Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials. As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates1 show that an overall ten per
cent improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around $800
million.

Physiomics develops computational systems biology models to predict and
understand cancer drug efficacy from pre-clinical research to clinical
development. Physiomics has created detailed mathematical models incorporating
most important molecular events taking place during the human cell cycle and
apoptosis processes. Physiomics developed SystemCell(R) technology, a multi-
cellular environment software, which enables the simulation of population of
'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM
in 2004. For further information, please visit www.physiomics-plc.com

SystemCell(R) is a registered trademark of Physiomics plc

1 Tufts Center Impact Report 2002


END

                      This information is provided by RNS
            The company news service from the London Stock Exchange               KDNCD